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Table 1. Comparison of cross-validated ROC AUCs for both 
endpoints. 
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Purpose/Objective: In this prospective study we investigated 
which anatomical structures that are related to trismus after 
radiation therapy in head and neck cancer (HNC). 
Materials and Methods: 216 consecutively included patients 
with HNC were prospectively followed regarding trismus both 
with respect to mouth opening measured in millimeters (MIO-
Maximal Interincisal Opening) and with validated patient-
reported outcome instruments (European Organization for 
Research and Treatment of Cancer Head and Neck 
Questionnaire (EORTC QLQ-HN35) and Gothenburg Trismus 
Questionnaire (GTQ)). Trismus was defined as any event 
during the first year of follow-up. Patients were assessed 
before radiotherapy and at 3, 6, and 12 months after 
completed oncological treatment. Mean absorbed doses of 
seven potential risk structures (masseter muscle, lateral and 
medial pterygoid muscle, temporal muscle, 
temporomandibular joint, soft palate, and, pterygopalatine 
ganglion (ipsi-, contra-, and bilateral)) were used in logistic 
regression analyses to create predictive models for radiation-
induced trismus.  
 
Results: For all three endpoints (MIO, GTQ, and, EORTC QLQ-
HN35,) we found that mean doses to the masseter muscle and 
the temporomandibular joint were statistically significant 
predictors for trismus. Results for ipsi-, and bilateral 
structures were comparable and the predictive ability given 
by the contralateral risk structures was lower in general. 
Smoking and height were significant risk factors for trismus 
according to MIO, and comorbidity (ACE-27) for trismus 
according to GTQ. Dose to the ipsilateral masseter as 
predictor for trismus according to GTQ, adjusted for ACE-27, 
provided the model with the overall strongest predictive 
ability (Az =0.78).  
Conclusions: Among seven risk structures, masseter muscle 
dose gives the strongest prediction of trismus. The masseter 
muscle may therefore be a possible candidate for future 
organ-sparing techniques to avoid trismus in cases where the 
masseter muscle dose can be safely lowered without 
jeopardizing tumor control. 
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Purpose/Objective: By collecting information from 
electronic health records of large numbers of patients, we 
have entered the era of rapid learning health care (RLHC). 
RLHC systems provide us with an ever-growing amount of 
data and pose the challenge to analyze these data in a 
meaningful way. One area to which RLHC is being applied is 
that of predicting acute dysphagia in non-small cell lung 
cancer (NSCLC) patients. 
Acute dysphagia occurs frequently during concurrent chemo-
radiation or high-dose radiotherapy for lung cancer. It is a 
dose limiting toxicity that can lead to treatment 
interruptions and thereby reduce chances of survival. 
Previously, we have developed models to predict this 
toxicity. However, the performance of these models is not 
perfect. This may be because these models were based on 
data from historical patients (e.g. 3D-CRT) which do not 
reflect current practice (e.g. IMRT and VMAT). In this study, 
we investigated whether a model, that attributes more 
weight to recent patient data in its training set, predicts 
dysphagia with a higher accuracy than a model that treats old 
and new data as equally important. 
Rectal Bleeding (RB)  Analytical Data-driven 
Radiogenomic 0.547 0.794 
Dosimetric 0.522 0.747 
Erectile Dysfunction (ED) Analytical Data-driven 
Radiogenomic 0.618 0.707 
Dosimetric 0.562 0.577 
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Materials and Methods: Clinical data from 469 inoperable 
NSCLC patients, treated with curative intent with 
chemoradiation (CRT) or radiotherapy (RT) alone were 
collected. The esophagus was delineated using the external 
esophageal contour from the cricoid cartilage to the GE 
junction. A Bayesian network model was developed to predict 
severe acute dysphagia (≥ Grade 3 according to the 
CTCAEv3.0). Data was weighted in proportion to how recent 
the RT took place. The model utilized gender, WHO 
performance status, mean esophageal dose, maximum 
esophageal dose and overall treatment time to make 
predictions. The model was trained on data from 363 
patients. The model’s performance was assessed on data 
from the 106 most recently treated patients and expressed as 
the Area Under the Curve (AUC) of the Receiver Operating 
Characteristic (ROC). The maximum value of the AUC is 1.0; 
indicating a perfect prediction model. A value of 0.5 
indicates that patients are correctly classified in 50% of the 
cases, e.g., as good as chance. Comparison of ROC curves 
was done using the method described in Hanley and McNeil 
(1983). 
Results: Fifty-one patients (11%) developed acute severe 
dysphagia. The model was validated on a dataset of 106 
recently treated patients. The AUC of the model that weights 
data based on its novelty was 0.69 (95%CI, 0.59–0.77) versus 
an AUC of 0.64 (95%CI, 0.54–0.73) for the model that treats 
all data with equal importance. The ROC curves are 
significantly different (P < 0.05).  
 
 
Conclusions: An increase in classification performance is 
observed by weighting data in proportion to how recent the 
treatment has occurred. The Bayesian network could be used 
in clinical practice to more accurately predict patients at 
high risk of developing acute dysphagia. Furthermore, this 
study shows the potential of rapid learning health care 
systems to develop and update prediction models for 
personalized treatment of cancer patients. 
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Purpose/Objective: Hodgkin Lymphoma (HL) survivors have 
an increased risk of cardiovascular disease (CVD), lung cancer 
and breast cancer. We estimated the risk of developing CVD 
and secondary lung, breast, and thyroid cancer after 
radiotherapy (RT) delivered with deep inspiration breath-hold 
(DIBH) compared to free-breathing (FB) using 3D conformal 
RT (3DCRT) and intensity modulated RT (IMRT). The aim of 
this study was to determine which treatment modality best 
reduced the combined risk of life-threatening late effects in 
patients with mediastinal HL. 
Materials and Methods: Twenty two patients with early 
stage, mediastinal HL were eligible for the study and 
underwent a pre-chemotherapy PET/CT-scan in DIBH and in 
FB as well as a post-chemotherapy CT-scan in DIBH and in FB. 
All treatment plans delivered 30.6 Gy to initially involved 
nodes using either 3DCRT or IMRT on both the DIBH- and FB-
sets, with equal target coverage requirements. We reported 
the estimated dose to the heart, lung, female breasts, and 
thyroid as well as the heterogeneity index (HI=Dmax 
PTV/(prescription dose)) and conformity index (CI= V95% 
body/Volume PTV) for each plan. The excess risks were 
calculated using dose-response relationships from large series 
of HL survivors with long-term follow-up (CD, lung cancer and 
breast cancer) and from the Childhood Cancer Survivor Study 
(thyroid cancer). The 'life-years lost' (LYL) measure was used 
compare the risks of late effects on a common scale 
(considering age-at-exposure, life-expectancy, and prognosis 
of the different late effects). Results were analyzed using a 
repeated measures analysis of variance (rANOVA) with 
treatment technique as a categorical variable (3D-DIBH, 
IMRT-DIBH, 3D-FB or IMRT-FB). 
Results: DIBH lowered the dose to heart and lung regardless 
of delivery technique (p<0.001), cf. figure 1. The mean 
breast dose was increased with IMRT regardless of breathing 
technique. There was no difference in HI between the 4 
categories of plans (p=0.3), whereas IMRT plans were 
consistently more conformal than 3DCRT with a median CI of 
2.5, 2.7, 1.2, and 1.2 for 3D-FB, 3D-DIBH, IMRT-FB, and IMRT-
DIBH, respectively. The overall lowest risk estimates for CVD 
and lung cancer were seen with IMRT-DIBH and for breast 
cancer with 3D-DIBH (see table 1). DIBH provided the lowest 
total LYL (with a range of 0.1-1.2 years for 3D-DIBH and 0.1-
1.3 for IMRT-DIBH) and FB the highest (0.1-1.7 and 0.1-1.8 for 
3D-FB and IMRT-FB respectively). For both DIBH and FB, 
3DCRT vs. IMRT were not significantly different in post hoc 
tests for LYL. 
 
 
